Condition: Epidermolysis Bullosa, Dystrophic · Epidermolysis Bullosa, Junctional · Sponsor: Amryt Pharma
In patients with epidermolysis bullosa (EB), collagen does not form properly, so their skin is very fragile and blisters easily. Such patients are also at greatly increased risk of developing skin cancers. Filsuvez is a topical gel used to promote healing of skin lesions in patients with certain types of EB. In this observational study, patients with either dystrophic EB (DEB) or junctional EB (JEB) will receive standard of care treatment, whether Filsuvez or something else, and will be followed for up to 5 years. The main purpose is to see if the use of Filsuvez affects the likelihood of developing skin malignancies in these patient populations.
This description comes directly from the study's public registry record.
Chiesi Clinical Trials · +3905212791 · clinicaltrials_info@chiesi.com
Always discuss trial participation with your own doctor first.
| CHU de Toulouse, Hôpital Larrey | Toulouse, France | Recruiting |
| Hospital of Skin and Venereal Diseases of Thessaloniki | Thessaloniki, Greece | Recruiting |
| Hospital Clinic, Barcelona | Barcelona, Spain | Recruiting |
| Hospital San Juan de Dios (Barcelona) | Barcelona, Spain | Recruiting |
| Guy's and St Thomas' NHS Foundation Trust | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06423573